The global typhoid fever vaccines market is estimated to be valued at USD 558.6 Mn in 2026 and is expected to reach a value of USD 1,244.0 Mn by 2033 at a CAGR of 12.2% between 2026 and 2033.
Drivers in the typhoid fever vaccines market include the high prevalence rate of typhoid fever in endemic areas, growing number of national immunization programs, and increased financial and infrastructural support from global health organizations like WHO, UNICEF, and Gavi. Higher awareness of vaccine-preventable diseases, better healthcare infrastructure, and government efforts for improving routine vaccination programs keep driving the market forward. Introduction of very effective typhoid conjugate vaccines (TCV), along with higher investment in public health campaigns, will drive market adoption. But poor accessibility to healthcare in distant locations and vaccine delivery issues are expected to be major restraints. There are opportunities available with broader immunization coverage, global funding programs, and adoption of advanced vaccines.
Based on Vaccine Types, Conjugate Vaccines are projected to lead the market with an estimated market share of 57.8% in 2026. The dominant position held by this segment is largely due to their good immunogenicity, sustained protection, excellent safety in infants and children, and high recommendations by the global health bodies. The incorporation of the same in the immunization schedule and the use in government-led vaccination drives further drive the demand.
According to the Route of Administration, the Parenteral category is predicted to command a market share of roughly 72.4% by 2026. The outstanding performance of the Parenteral category is attributed to the superior effectiveness of injectable typhoid conjugate vaccines, ease of integration into the childhood vaccination program, high vaccination rate, and approval of the product by the government and other stakeholders.
Geographically, the Asia Pacific region is expected to dominate the typhoid fever vaccines market with a market share of 47.3% in 2026 due to the high incidence of typhoid fever, government-sponsored vaccination programs, support from international agencies, and growing usage of typhoid conjugate vaccines in South Asian countries. Africa is forecasted to be the leading region, fueled by vaccination programs, increasing awareness regarding waterborne diseases, strengthening healthcare infrastructure, growing international funds, and collaborations among governments and international health agencies for improved accessibility to vaccines.
Prominent Players in the Typhoid Fever Vaccines Market
-
GlaxoSmithKline plc (GSK)
Company Overview
- Headquarters: London, England, United Kingdom
- Establishment Year: 2000
- Employee Strength: Approximately 70,000 employees
- Leadership: Ms. Emma Walmsley, Chief Executive Officer
- Core Services/Products: Vaccines, prescription medicines, infectious disease vaccines, respiratory therapies, immunology products, and pediatric vaccines.
SWOT Analysis
- Strengths
- Most dominant firm in terms of vaccine manufacturing and marketing.
- Global distribution and collaboration with public health bodies.
- Weaknesses
- High dependency on innovations and regulatory procedures.
- Extensive investments in research and development reduce profit margins.
- Opportunities
- Moving into immunization programs in developing nations backed by the government.
- Greater demand for travel vaccines and pediatric vaccines.
- Threats
- High competition among multinational vaccine companies.
- Bargaining power of public health procurement authorities.
-
Sanofi SA
Company Overview
- Headquarters: Paris, France
- Establishment Year: 1973
- Employee Strength: Approximately 91,000 employees
- Leadership: Mr. Paul Hudson, Chief Executive Officer
- Core Services/Products: Vaccines, specialty pharmaceuticals, pediatric vaccines, infectious disease vaccines, biologics, and immunization solutions through Sanofi Pasteur.
SWOT Analysis
- Strengths
- Global reach in terms of human vaccines and prevention of infectious diseases.
- High manufacturing capability that is backed by research in vaccines.
- Weaknesses
- High costs associated with production and compliance.
- Government procurement for several vaccines.
- Opportunities
- Benefits of increased vaccination program in terms of routine immunizations.
- The need for combination and advanced generation vaccines.
- Threats
- Disturbance in the supply chain that results in problems in vaccine production.
- Competition from vaccine manufacturers in other regions.
-
Bharat Biotech
Company Overview
- Headquarters: Hyderabad, Telangana, India
- Establishment Year: 1996
- Employee Strength: Approximately 1,600 employees
- Leadership: Dr. Krishna M. Ella, Executive Chairman
- Core Services/Products: Vaccines, typhoid conjugate vaccines, viral vaccines, pediatric vaccines, biotechnology products, and global immunization solutions.
SWOT Analysis
- Strengths
- High competency in designing low-cost vaccines for the developing world.
- Skills in vaccine research and production at high volume.
- Weaknesses
- Dependence on vaccine-related products, more than other diversified pharma companies.
- Income affected by the purchase cycle of the government.
- Opportunities
- Popular use of typhoid conjugate vaccines in national immunization schedules.
- Diversification into international vaccine markets using global alliances.
- Threats
- Intense competition from other multinational vaccine makers.
- Low tolerance to stringent regulations worldwide.
-
Bio-Med Pvt. Ltd.
Company Overview
- Headquarters: Ghaziabad, Uttar Pradesh, India
- Establishment Year: 1969
- Employee Strength: Approximately 500 employees
- Leadership: Mr. Rajesh Gupta, Managing Director
- Core Services/Products: Vaccines, biological products, diagnostic reagents, immunization products, and pharmaceutical manufacturing.
SWOT Analysis
- Strengths
- Experience in producing biological and vaccine products.
- Excellent experience in supplying healthcare products to domestic market.
- Weaknesses
- Tiny presence across the globe when compared to multinational vaccine organizations.
- Limited range of products and production scale.
- Opportunities
- Increasing government expenditure on vaccination programs.
- Increasing scope through partnerships and contract manufacturing.
- Threats
- Increased competition from large multinational vaccine producers.
- Changing regulations for biological products.
-
PT Bio Farma
Company Overview
- Headquarters: Bandung, Indonesia
- Establishment Year: 1890
- Employee Strength: Approximately 1,300 employees
- Leadership: Mr. Shadiq Akasya, President Director
- Core Services/Products: Human vaccines, typhoid vaccines, pediatric vaccines, biological products, plasma derivatives, and immunization solutions.
SWOT Analysis
- Strengths
- Largest vaccine maker behind Indonesia’s nationwide vaccination campaign.
- Good proficiency in vaccine manufacturing with WHO approved vaccines.
- Weaknesses
- Dependency on public sector purchases.
- No presence in other markets except for major international ones.
- Opportunities
- Rising requirement for vaccines in Southeast Asia and Africa.
- Business expansion via global health partnerships and exports.
- Threats
- Multinational companies operating in vaccine manufacturing.
- Regulatory risks and fluctuations in healthcare budget allocations by government.
